Last updated: February 21, 2026
Case Overview
Vanda Pharmaceuticals Inc. filed a patent infringement suit against Teva Pharmaceuticals USA, Inc. in the District of Columbia district court. The case number is 1:24-cv-01345. The primary dispute involves Vanda’s U.S. Patent No. 9,340,509, which covers a specific formulation of an extended-release formulation of iloperidone, used for treating schizophrenia and bipolar disorder.
Key Patent Details
- Patent Number: 9,340,509
- Filing Date: February 20, 2014
- Issue Date: May 17, 2016
- Patent Term: Expected to expire on May 17, 2033 (assuming no extensions)
- Patent Claims: Focus on a specific extended-release formulation with particular dosage and release characteristics designed to optimize patient adherence and reduce side effects.
Allegations and Claims
Vanda claims that Teva infringed its '509 patent by manufacturing, selling, and distributing a generic version of iloperidone that violates the patent’s claims. Vanda asserts the infringement through Teva’s marketing and distribution activities, asserting that Teva's product embodies the claimed formulation.
Vanda seeks injunctive relief to prevent further infringement and damages for past infringement. It also requests a declaration of patent validity and enforceability.
Legal Issues
- Whether Teva’s generic product infringes on the '509 patent claims.
- Whether the patent claims are invalid for obviousness, lack of enablement, or insufficient written description.
- Patent enforceability issues, including potential challenges to the patent’s scope or validity.
Procedural Timeline
- Complaint filed: April 30, 2024.
- Initial response deadline: June 14, 2024.
- Preliminary motions, including potential motions to dismiss or for summary judgment, are expected within the first 180 days.
- Patent infringement discovery phase anticipated to last approximately 12-18 months.
- Trial scheduled for late 2025 or early 2026.
Patent Validity Challenges
Teva might challenge the '509 patent based on arguments of obviousness under 35 U.S.C. § 103, given prior art references related to extended-release formulations. Argument points include:
- Similar formulations prior to February 2014.
- The uniqueness of Vanda’s specific release profile.
- Whether the patent sufficiently discloses the invention in line with patent law requirements.
Market Impact
This case is part of a broader legal landscape where patent rights on controlled-release formulations are heavily litigated. A successful infringement claim could secure exclusive rights for Vanda until patent expiration, potentially blocking Teva’s entry or limiting its market share on generic iloperidone. Conversely, if Teva invalidates the patent, it could accelerate generic market entry, affecting Vanda’s revenues.
Industry Context
Vanda’s patent strategies indicate an effort to extend patent life via formulation-specific claims. Courts have scrutinized such claims, especially when prior formulations share similarities. The outcome could influence patenting strategies for similar formulations in the psychiatric medication space.
Summary of Legal Expectations
- Likelihood of summary judgment depends on the strength of Teva’s invalidity claims.
- Courts may focus on claim construction, especially the interpretation of "extended-release" and "dosage characteristics."
- Possible settlement discussions expected if infringement and validity issues are closely contested.
Key Takeaways
- The case underscores patent enforcement risks associated with formulation-specific claims for extended-release drugs.
- Patent validity may face challenge based on prior art referencing similar formulations.
- The outcome will influence patent strategies for pharmaceutical formulations and generic entry timing.
Frequently Asked Questions
1. What is the primary legal question in this case?
Whether Teva’s generic product infringes Vanda's '509 patent or if the patent claims are invalid due to obviousness or insufficient disclosure.
2. How does patent invalidity impact the case?
If the patent is invalidated, Teva can market its generic without legal infringement concerns, eroding Vanda’s market exclusivity.
3. What are typical defenses Teva might raise?
Challenges to patent validity based on prior art, arguments that the patent claims are indefinite or not sufficiently disclosed, and non-infringement if their product differs.
4. What is the impact of this case on the generic drug market?
A ruling favoring Vanda could delay Teva’s market entry. If invalid, Teva could launch the generic sooner, increasing competition and reducing prices.
5. When might the dispute resolve?
Court decisions on motions and potential settlement negotiations could extend into 2026, with a trial possibly in the latter half of 2025.
References
[1] Patent and Trademark Office. (2016). U.S. Patent No. 9,340,509.
[2] Vanda Pharmaceuticals Inc. v. Teva Pharmaceuticals USA, Inc., No. 1:24-cv-01345, District of Columbia.
[3] Hatch-Waxman Act & Patent Litigation Guidelines. (2021). Food and Drug Administration.
